Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

18 results

Filters applied: . Clear all
Page 1
COVID-19 outbreak in Italy: an opportunity to evaluate extended interval dosing of ocrelizumab in MS patients.
Bisecco A, Matrone F, Capobianco M, De Luca G, Filippi M, Granella F, Lus G, Marfia GA, Mirabella M, Patti F, Trojano M, Mascolo A, Copetti M, Tedeschi G, Gallo A; OCREVID study group on behalf of the Italian MS Register. Bisecco A, et al. Among authors: mirabella m. J Neurol. 2024 Feb;271(2):699-710. doi: 10.1007/s00415-023-12084-4. Epub 2023 Nov 20. J Neurol. 2024. PMID: 37982852 Free PMC article.
DISCUSSION: Despite the significant extension of OCR infusion interval during the first wave of pandemic in Italy, a very small incidence of clinical/radiological events was observed, thus suggesting durable efficacy of OCR, as well as the absence of rebound after its short-te …
DISCUSSION: Despite the significant extension of OCR infusion interval during the first wave of pandemic in Italy, a very small incidence of …
Assessing treatment response to oral drugs for multiple sclerosis in real-world setting: a MAGNIMS Study.
Ruggieri S, Prosperini L, Al-Araji S, Annovazzi PO, Bisecco A, Ciccarelli O, De Stefano N, Filippi M, Fleischer V, Evangelou N, Enzinger C, Gallo A, Garjani A, Groppa S, Haggiag S, Khalil M, Lucchini M, Mirabella M, Montalban X, Pozzilli C, Preziosa P, Río J, Rocca MA, Rovira A, Stromillo ML, Zaffaroni M, Tortorella C, Gasperini C; MAGNIMS Study Group. Ruggieri S, et al. Among authors: mirabella m. J Neurol Neurosurg Psychiatry. 2024 Jan 11;95(2):142-150. doi: 10.1136/jnnp-2023-331920. J Neurol Neurosurg Psychiatry. 2024. PMID: 37775266
CONCLUSIONS: Early relapses and substantial MRI activity in the first year of treatment are associated with worse short-term outcomes in patients treated with some of the oral DMTs....
CONCLUSIONS: Early relapses and substantial MRI activity in the first year of treatment are associated with worse short-term outcomes …
Early sclerostin assessment in frail elderly patients with sepsis: insights on short- and long-term mortality prediction.
Tirandi A, Arboscello E, Ministrini S, Liberale L, Bonaventura A, Vecchié A, Bertolotto M, Giacobbe DR, Castellani L, Mirabella M, Minetti S, Bassetti M, Montecucco F, Carbone F. Tirandi A, et al. Among authors: mirabella m. Intern Emerg Med. 2023 Aug;18(5):1509-1519. doi: 10.1007/s11739-023-03223-w. Epub 2023 Mar 21. Intern Emerg Med. 2023. PMID: 36943596 Free PMC article.
Thirty-day mortality was set as primary outcome. In-hospital and long-term mortality (2.5 years of median follow-up) were assessed as secondary outcomes. ...The degree of this variation further predicted long-term mortality (HR for delta SOST T0-day 14: 1.006 with 9 …
Thirty-day mortality was set as primary outcome. In-hospital and long-term mortality (2.5 years of median follow-up) were assessed as …
Treatment Challenges in Multiple Sclerosis - A Continued Role for Glatiramer Acetate?
Mirabella M, Annovazzi P, Brownlee W, Cohen JA, Kleinschnitz C, Wolf C. Mirabella M, et al. Front Neurol. 2022 Apr 15;13:844873. doi: 10.3389/fneur.2022.844873. eCollection 2022. Front Neurol. 2022. PMID: 35493825 Free PMC article. Review.
Earlier diagnosis, access to disease-modifying therapies (DMTs), and improved supportive care have favorably altered the disease course of multiple sclerosis (MS), leading to an improvement in long-term outcomes for people with MS (PwMS). This success has changed the medic …
Earlier diagnosis, access to disease-modifying therapies (DMTs), and improved supportive care have favorably altered the disease course of m …
Immune Response of Neonates Born to Mothers Infected With SARS-CoV-2.
Conti MG, Terreri S, Piano Mortari E, Albano C, Natale F, Boscarino G, Zacco G, Palomba P, Cascioli S, Corrente F, Capponi C, Mirabella M, Salinas AF, Marciano A, De Luca F, Pangallo I, Quaranta C, Alteri C, Russo C, Galoppi P, Brunelli R, Perno CF, Terrin G, Carsetti R. Conti MG, et al. Among authors: mirabella m. JAMA Netw Open. 2021 Nov 1;4(11):e2132563. doi: 10.1001/jamanetworkopen.2021.32563. JAMA Netw Open. 2021. PMID: 34730817 Free PMC article.
IMPORTANCE: Although several studies have provided information on short-term clinical outcomes in children with perinatal exposure to SARS-CoV-2, data on the immune response in the first months of life among newborns exposed to the virus in utero are lacking. ...DESIGN, SE …
IMPORTANCE: Although several studies have provided information on short-term clinical outcomes in children with perinatal exposure to …
Long-term Follow-up and Muscle Imaging Findings in Brachio-Cervical Inflammatory Myopathy.
Lucchini M, Bortolani S, Monforte M, Papacci M, Ricci E, Mirabella M, Tasca G. Lucchini M, et al. Among authors: mirabella m. Neurol Neuroimmunol Neuroinflamm. 2021 May 19;8(4):e1016. doi: 10.1212/NXI.0000000000001016. Print 2021 Jul. Neurol Neuroimmunol Neuroinflamm. 2021. PMID: 34011678 Free PMC article.
CONCLUSION: BCIM is an inflammatory myopathy with a peculiar clinical and radiologic presentation and a relatively broad spectrum of severity. Long-term follow-up data suggest that appropriate and early treatment can prevent chronic muscle function impairment. ...
CONCLUSION: BCIM is an inflammatory myopathy with a peculiar clinical and radiologic presentation and a relatively broad spectrum of severit …
Efficacy and Safety of Bimagrumab in Sporadic Inclusion Body Myositis: Long-term Extension of RESILIENT.
Amato AA, Hanna MG, Machado PM, Badrising UA, Chinoy H, Benveniste O, Karanam AK, Wu M, Tankó LB, Schubert-Tennigkeit AA, Papanicolaou DA, Lloyd TE, Needham M, Liang C, Reardon KA, de Visser M, Ascherman DP, Barohn RJ, Dimachkie MM, Miller JAL, Kissel JT, Oskarsson B, Joyce NC, Van den Bergh P, Baets J, De Bleecker JL, Karam C, David WS, Mirabella M, Nations SP, Jung HH, Pegoraro E, Maggi L, Rodolico C, Filosto M, Shaibani AI, Sivakumar K, Goyal NA, Mori-Yoshimura M, Yamashita S, Suzuki N, Aoki M, Katsuno M, Morihata H, Murata K, Nodera H, Nishino I, Romano CD, Williams VSL, Vissing J, Zhang Auberson L; RESILIENT Study Extension Group. Amato AA, et al. Among authors: mirabella m. Neurology. 2021 Mar 23;96(12):e1595-e1607. doi: 10.1212/WNL.0000000000011626. Epub 2021 Feb 17. Neurology. 2021. PMID: 33597289 Free PMC article. Clinical Trial.
OBJECTIVE: To assess long-term (2 years) effects of bimagrumab in participants with sporadic inclusion body myositis (sIBM). ...CLASSIFICATION OF EVIDENCE: This study provides Class IV evidence that for patients with sIBM, long-term treatment with bimagrumab was saf …
OBJECTIVE: To assess long-term (2 years) effects of bimagrumab in participants with sporadic inclusion body myositis (sIBM). ...CLASS …
A pilot study of lncRNAs expression profile in serum of progressive multiple sclerosis patients.
Santoro M, Nociti V, Lucchini M, Loiodice M, Centofanti F, Botta A, Losavio FA, De Fino C, Mirabella M. Santoro M, et al. Among authors: mirabella m. Eur Rev Med Pharmacol Sci. 2020 Mar;24(6):3267-3273. doi: 10.26355/eurrev_202003_20694. Eur Rev Med Pharmacol Sci. 2020. PMID: 32271444 Free article.
The relapsing and the eventually progressive course of MS is heterogeneous; thus, a confident long-term prediction of individual prognosis is not possible yet. Recent studies have demonstrated the role of long non-coding RNA (lncRNAs) as potential biomarkers that could pro …
The relapsing and the eventually progressive course of MS is heterogeneous; thus, a confident long-term prediction of individual prog …
Exit strategies for "needle fatigue" in multiple sclerosis: a propensity score-matched comparison study.
Prosperini L, Cortese A, Lucchini M, Boffa L, Borriello G, Buscarinu MC, Capone F, Centonze D, De Fino C, De Pascalis D, Fantozzi R, Ferraro E, Filippi M, Galgani S, Gasperini C, Haggiag S, Landi D, Marfia G, Mataluni G, Millefiorini E, Mirabella M, Monteleone F, Nociti V, Pontecorvo S, Romano S, Ruggieri S, Salvetti M, Tortorella C, Zannino S, Di Battista G. Prosperini L, et al. Among authors: mirabella m. J Neurol. 2020 Mar;267(3):694-702. doi: 10.1007/s00415-019-09625-1. Epub 2019 Nov 13. J Neurol. 2020. PMID: 31720848
Patients with multiple sclerosis on long-term injectable therapies may suffer from the so-called "needle fatigue", i.e., a waning commitment to continue with the prescribed injectable treatment. ...The low number of patients who relapsed over the 12-month follow-up (25 out …
Patients with multiple sclerosis on long-term injectable therapies may suffer from the so-called "needle fatigue", i.e., a waning com …
Drug Holiday of Interferon Beta 1b in Multiple Sclerosis: A Pilot, Randomized, Single Blind Study of Non-inferiority.
Romano S, Ferraldeschi M, Bagnato F, Mechelli R, Morena E, Caldano M, Buscarinu MC, Fornasiero A, Frontoni M, Nociti V, Mirabella M, Mayer F, Bertolotto A, Pozzilli C, Vanacore N, Salvetti M, Ristori G. Romano S, et al. Among authors: mirabella m. Front Neurol. 2019 Jul 16;10:695. doi: 10.3389/fneur.2019.00695. eCollection 2019. Front Neurol. 2019. PMID: 31379701 Free PMC article.
Conclusions: A calendar with CW was non-inferior than FR at the beginning of IFN-b therapy, and may not affect the long-term outcome. Clinical Trial Registration: www.ClinicalTrials.gov, identifier: NCT00270816....
Conclusions: A calendar with CW was non-inferior than FR at the beginning of IFN-b therapy, and may not affect the long-term outcome. …
18 results